Search
01/11/2023
The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.
Cordero A, Fernández Olmo R, Badimon L, Santos-Gallego CG, Castellano JM, Fácila L, Rodriguez-Manero M, Bonanad C, Vilahur G, Escribano D, Badimon JJ, González-Juanatey JR. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.. Journal of Clinical Lipidology. 2023; 17(5)DOI:10.1016/j.jacl.2023.08.006. PMID:37775463. IF:3.600(Q2/3D).
01/01/2026
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, GO, Otero, S, Nikolaou, PE, Alcover, S, Ramos-Regalado, L, Zaragoza, C, Liberale, L, Borrell-Pages, M, Padró, T, Suades, R, Vilahur, G. Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2026; 56(1)DOI:10.1111/eci.70167. PMID:41482986. IF:3.600(Q1/2D).
01/05/2025
Canonical WNT pathway role in heart-brain axis after myocardial
Pimentel, N, Luquero, A, Vilahur, G, Borrel-Pages, M. Canonical WNT pathway role in heart-brain axis after myocardial. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2025; 55DOI:. PMID:. IF:3.600(Q1/2D).
01/01/2026
miRNA Expression Profile in Whole Blood of Healthy Volunteers and Moderate Beer Consumption with Meals
Padro, T, Escate, R, Badimon, L. miRNA Expression Profile in Whole Blood of Healthy Volunteers and Moderate Beer Consumption with Meals. Nutrients. 2026; 18(1)DOI:10.3390/nu18010149. PMID:41515265. IF:5.000(Q1/2D).